Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-Cell responses to the tumor-specific antigen NY-ESO-1

被引:54
|
作者
Le Gal, FA
Ayyoub, M
Dutoit, V
Widmer, V
Jäger, E
Cerottini, JC
Dietrich, PY
Valmori, D
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Med, Ludwig Inst,Clin Trial Ctr,Div Med Oncol, New York, NY 10032 USA
[2] Univ Hosp Geneva, Div Oncol, Lab Tumor Immunol, Geneva, Switzerland
[3] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[4] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
T-cell receptor; repertoire; tumor immunity; vaccination;
D O I
10.1097/01.cji.0000161398.34701.26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epilope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines. but they are heterogeneous in terms of functional avidity and tumor reactivity, The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may rail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 11 条
  • [1] Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination
    Karbach, Julia
    Gnjatic, Sacha
    Pauligk, Claudia
    Bender, Armin
    Maeurer, Markus
    Schultze, Joachim L.
    Nadler, Kerstin
    Wahle, Claudia
    Knuth, Alexander
    Old, Lloyd J.
    Jaeger, Elke
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (09) : 2042 - 2048
  • [2] Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    Yuan, Jianda
    Adamow, Matthew
    Ginsberg, Brian A.
    Rasalan, Teresa S.
    Ritter, Erika
    Gallardo, Humilidad F.
    Xu, Yinyan
    Pogoriler, Evelina
    Terzulli, Stephanie L.
    Kuk, Deborah
    Panageas, Katherine S.
    Ritter, Gerd
    Sznol, Mario
    Halaban, Ruth
    Jungbluth, Achim A.
    Allison, James P.
    Old, Lloyd J.
    Wolchok, Jedd D.
    Gnjatic, Sacha
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (40) : 16723 - 16728
  • [3] Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
    Song, Mi-Young
    Park, Sang-Hoon
    Nam, Hyo Jung
    Choi, Dong-Hoon
    Sung, Young-Chul
    JOURNAL OF IMMUNOTHERAPY, 2011, 34 (03) : 297 - 306
  • [4] CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg
    Ayyoub, Maha
    Pignon, Pascale
    Classe, Jean-Marc
    Odunsi, Kunle
    Valmori, Danila
    CANCER IMMUNOLOGY RESEARCH, 2013, 1 (05) : 303 - 308
  • [5] Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1
    Matsuzaki, Junko
    Qian, Feng
    Luescher, Immanuel
    Lele, Shashikant
    Ritter, Gerd
    Shrikant, Protul A.
    Gnjatic, Sacha
    Old, Lloyd J.
    Odunsi, Kunle
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (08) : 1185 - 1195
  • [6] Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity
    Tsuji, Takemasa
    Matsuzaki, Junko
    Kelly, Marcus P.
    Ramakrishna, Venky
    Vitale, Laura
    He, Li-Zhen
    Keler, Tibor
    Odunsi, Kunle
    Old, Lloyd J.
    Ritter, Gerd
    Gnjatic, Sacha
    JOURNAL OF IMMUNOLOGY, 2011, 186 (02) : 1218 - 1227
  • [7] Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1
    Junko Matsuzaki
    Feng Qian
    Immanuel Luescher
    Shashikant Lele
    Gerd Ritter
    Protul A. Shrikant
    Sacha Gnjatic
    Lloyd J. Old
    Kunle Odunsi
    Cancer Immunology, Immunotherapy, 2008, 57 : 1185 - 1195
  • [8] Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide
    Eikawa, Shingo
    Kakimi, Kazuhiro
    Isobe, Midori
    Kuzushima, Kiyotaka
    Luescher, Immanuel
    Ohue, Yoshihiro
    Ikeuchi, Kazuhiro
    Uenaka, Akiko
    Nishikawa, Hiroyoshi
    Udono, Heiichiro
    Oka, Mikio
    Nakayama, Eiichi
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) : 345 - 354
  • [9] Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease
    Wang, XY
    Kazim, L
    Repasky, EA
    Subjeck, JR
    INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (02) : 226 - 231
  • [10] Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
    Christian Bauer
    Alexander Sterzik
    Franz Bauernfeind
    Peter Duewell
    Claudius Conrad
    Rosemarie Kiefl
    Stefan Endres
    Andreas Eigler
    Max Schnurr
    Marc Dauer
    Cancer Immunology, Immunotherapy, 2014, 63 : 321 - 333